Drinking Alcohol is Fatal for People Affected with Hepatitis C Virus: Case Study
Drinking alcohol severely increases the risks of liver damage and death from the Hepatitis C virus, reveals a study published by Centre for Disease Control and Prevention’s Division of Viral Hepatitis. According to this study, several people living with acute Hepatitis C are either former or current excessive alcohol drinkers.
Alcohol Abuse and Hepatitis
As per the findings, alcohol abuse is one of the leading causes of Hepatitis. But, it is also detrimental for people, who are currently under the hepatitis treatment. Among all the forms, Hepatitis C virus is considered the worst, since in most cases, this becomes a terminal illness and no conventional treatment procedure can actually put it to an end. It’s been found that the person affected with hepatitis infection is more likely to drink five or more drinks per day.
According to National Centre for Disease Control, nearly 119,000 cases of viral hepatitis were reported in India in 2012. The numbers have probably increased in the recent times. The Integrated Disease Surveillance Programme of the NCDC has also received notification of 290,000 cases of acute viral hepatitis in 2013. Most cases have been reported from Gujarat (17.1%), Tamil Nadu (12.7%), Uttar Pradesh (11.8%), West Bengal (7.3%) and Madhya Pradesh (7.3%). The deadly Hepatitis C virus afflicts as many as 150 million people worldwide and possibly 12 million in India.
As mentioned earlier, the treatment options for hepatitis C Virus is extremely limited, but recently, However, a globally renowned pharmaceutical house has declared about their latest breakthrough “Epclusa” recently, which is supposed to bring a thorough revival in the treatment of Hepatitis C virus. They have claimed that “Epclusa” will be highly effective in treating all genotypes of the Hepatitis C virus. The best part it has been already approved by the US Food and Drug Administration (FDA).
In order to make hepatitis treatment affordable, the manufacturer has introduced this product. Since, India’s capability in generic manufacturing is restricted by financial constraints, the pharmaceutical houses are always in the pressure of creating life saving cures that can be widely accessible in the low income countries around the world. Epclusa, the drug for treating hepatitis C infection is one such product by the manufacturer that can be accessible to a large number of patients.
According to Ira Jacobson, MD, chairman of the Department of Medicine at Mount Sinai Beth Israel, New York and a principal investigator in the Epclusa clinical trials, “The approval of Epclusa represents an important step forward in the global effort to control and potentially eliminate HCV as it provides a safe, simple and effective cure for the majority of HCV-infected patients, regardless of genotype”.